6-Bromo-3-Hydroxypyrazine-2-Carboxamide CAS 259793-88-9 Purity ≥99.0% Favipiravir Intermediate COVID-19

Short Description:

Name: 6-Bromo-3-Hydroxypyrazine-2-Carboxamide

CAS: 259793-88-9 

Purity: ≥99.0%

Intermediate of Favipiravir (CAS 259793-96-9) in the treatment of Influenza virus infections and COVID-19

High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com

Product Detail

Related Products

Product Tags


Chemical Properties:

Chemical Name 6-Bromo-3-Hydroxypyrazine-2-Carboxamide
Synonyms Favipiravir Intermediate; Favipiravir Impurity 4
CAS Number 259793-88-9
CAT Number RF-PI296
Stock Status In Stock, Production Scale Up to Hundreds of Kilograms
Molecular Formula C5H4BrN3O2
Molecular Weight 218.01
Brand Ruifu Chemical


Item Specifications
Appearance Light Yellow to Brown Powder
Identification  IR, HPLC
Loss on Drying ≤1.0%
Residue on Ignition ≤0.20% 
Single Impurity ≤0.50%
Total Impurities ≤1.0%
Heavy Metals ≤20ppm
Residual Solvents Meet the specification
Test Standard Enterprise Standard
Usage Intermediate of Favipiravir (CAS 259793-96-9) 

Package & Storage:

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.





6-Bromo-3-Hydroxypyrazine-2-Carboxamide (CAS 259793-88-9) is an intermediate typically in the synthesis of 6-Bromo-3-Hydroxypyrazine-2-Carboxamide commercially named Favipiravir (CAS 259793-96-9) in the treatment of Influenza virus infections. A practical and step-economic route to Favipiravir. Favipiravir is a COVID19-related research product, in the treatment of patients with COVID-19 recommended by WHO. Favipiravir, also known as T-705 or Avigan, is an antiviral drug being developed by Toyama Chemical (Fujifilm Group) of Japan with activity against many RNA viruses. Favipiravir was approved for marketing in Japan in March 2014 and used for antiviral treatment of influenza A and B. In addition to the influenza virus, the drug also showed good antiviral activity to a variety of RNA viruses, such as Ebola virus, sand virus, Bunia virus, rabies virus, etc. In February 2020 Favipiravir was being studied in China for experimental treatment of the emergent COVID-19 (Novel Coronavirus) disease and it has show positive results.

  • Write your message here and send it to us